Organic Active Ingredients TRIZ Cases

Antisense oligonucleotides reduce glucagon receptor expression to regulate blood glucose levels.

Compound 1 oral prostanoid treats Raynaud's by improving digital blood flow and reducing attack frequency.

A thickened iontophoretic composition drives S-ketamine transdermal absorption via electric field repulsion.

Novel dihydroquinolizinone compounds inhibit hepatitis B surface antigen production and secretion, addressing persistent infection in chronic patients.

EthoGel transdermal system delivers NSAIDs via hydrogel carrier and blunted spike applicator, resolving limited skin permeation rates.

Oral glucagon-like peptide-1 receptor agonists employ absorption enhancers to bypass injection barriers and enable convenient once-daily dosing.

Selective heteroaryl inhibitors target exon 20 insertion mutations while sparing wild-type EGFR to reduce toxicity.

Introducing a phosphonomethoxy group at the 3' position resolves the contradiction between therapeutic efficacy and STING modulation capability.

BMP9 agonists restore anoikis sensitivity to suppress metastasis despite chemotherapy resistance.

A low-moisture HPMC capsule shell protects enterically coated 5-aminosalicylic acid tablets from environmental degradation.

Triazole derivatives combine beta-2 agonist and muscarinic antagonist pharmacologies into single molecules for inhalation therapy.

Synthesized benzamide derivatives preserve farnesylthio groups to inhibit KRAS, overcoming limited efficacy of existing inhibitors.

Small molecule compounds activate RET signaling to promote neuronal survival while bypassing blood-brain barrier limitations of protein therapies.

Combining amitriptyline with mefloquine inhibits central nervous system hemichannels to potentiate therapeutic effects.

Asymmetric siRNA targets MARC1 mRNA to inhibit gene expression, resolving safety issues in non-alcoholic fatty liver disease treatment.

Administering specific antimicrobial peptides to reset colon microbial balance and alleviate irritable bowel syndrome symptoms.

Novel aptamer SEQ ID NO: 1 delays vitamin C oxidation to improve cognitive function in aging models.

Specific compounds displace unstable water molecules in the TYK2 kinase binding pocket to enhance binding affinity.

D-methadone modulates the NMDA receptor and up-regulates brain-derived neurotrophic factor levels, delivering neuroprotection without opioid side effects.

A probiotic formulation comprising Pediococcus acidilactici and Leuconostoc mesenteroides increases microbial genes associated with mannitol production.

Evaluating IL-17 concentration in peripheral blood mononuclear cells identifies patients responsive to glatiramer acetate.

A nutritional supplement combining naringin and neohesperidin from bitter orange pith to improve oral bioavailability.

Quinoline derivatives bind the bromodomain of BRD4 to block acetylated histone interaction.

Micelle-laden hydrogels incorporate surfactants to form cross-linked polymeric matrices that facilitate stable nanocrystal production within micelle cores.

A nanotopography-mediated reverse uptake platform delivers siRNA into neural stem cells using self-assembled silicon oxide nanoparticle monolayers.

Crystalline osanetant salts resolve instability issues by improving thermal profiles and manufacturing reproducibility.

Engineered monocytes express recombinant nucleic acids encoding autoimmune antigens to induce specific immune tolerance.

Formula Ia to III compounds treat multidrug-resistant tuberculosis while reducing side effects and improving patient compliance.

A mild coupling method generates phosphoramidates using dialkylazodicarboxylate, phosphine, and amine reagents in an aprotic solvent.

Alpha-glucosidase digestion of low acyl gellan gum produces midi and mini fragments that cross the blood-brain barrier to treat neurodegenerative disorders.

Novel exatecan antibody-drug conjugates deliver cytotoxic payloads to tumor cells via targeted binding mechanisms.

Plasma cholinesterase rapidly hydrolyzes these compounds into inactive metabolites, eliminating systemic side effects while maintaining therapeutic efficacy.

DGAT1 inhibition reduces inflammatory infiltrates and delays disease severity in multiple sclerosis models.

A novel isoindoline-dione compound treats hematological malignancies through targeted molecular mechanisms.

Colon-release coatings deliver cholestyramine to the large intestine, preventing small intestine drug interactions.

CXD101 potentiates vaccine efficacy by augmenting MHC expression and T-cell responses.

Anhydrous dispersion medium suspends pyrimethamine particles, resolving water solubility limits and enabling stable pediatric liquid administration.

Targeted NPSR modulation treats narcolepsy, insomnia, and asthma by balancing wakefulness and bronchial tone without broad systemic effects.

Segmented functional layers resist gastric acid and dissolve at intestinal pH, ensuring precise budesonide release in the distal colon.

A processor adjusts osmotic agent concentration during a dialysis cycle to enhance fluid removal efficiency.

Structurally modified celastrol compounds address limited anti-obesity treatments by promoting sustainable weight loss and improving glucose homeostasis.

Segmented coated particles with polymer matrices stabilize plasma concentrations and improve patient compliance by eliminating rapid absorption fluctuations.

Topical itraconazole solution prevents infection recurrence by delivering concentrated antimicrobial agents directly to infected skin surfaces.